Financial Wire

Celestica Price Target Raised to US$425 at CIBC

-- CIBC Capital Markets raised its price target on Celestica Inc. (CLS.TO, CLS) to US$425 from US$360.

Analyst Todd Coupland maintained an Outperformer rating on shares of the Canadian electronics manufacturing services company ahead of its fiscal Q1 results on April 27.

"We continue to view management's guidance - and current FactSet consensus for Q1 and 2026 - as conservative, reflecting improved visibility into capex plans at key hyperscalers (GOOGL, META, AMZN) and OpenAI," Coupland said in a note to clients.

"Since March 2022, results have exceeded consensus by an average of ~5% on revenue and ~10% on EPS," the analyst said. "Notably, the 2025 results were ~20% higher than the initial Outlook provided in October 2024."

"Recent announcements suggest this trend has continued and is pulling forward customer demand from 2027 into 2026, supporting our positive thesis," Coupland said.

"We raised our target multiples for Celestica to reflect improved visibility to upward revisions in AI datacentre capex spending from significantly improved model performance."

Related Articles

Australia

Yum! Brands Expected to Deliver 'Low-Controversy' Q1, RBC Says

Yum! Brands (YUM) is expected to report a "relatively low-controversy" Q1, RBC Capital Markets said Sunday in a report.The Taco Bell US business likely continued to outperform compared with the broader quick-service category, with buy-side same-store sales expectations at least a few hundred basis points above the sell-side's 4.9% estimate, the report said.For KFC International, a key focus in the earnings call will be any impact on international demand from higher fuel prices due to the conflict in the Middle East, the report said.RBC said it doesn't expect a "meaningful" update on Pizza Hut's strategic review with the bidding process likely still underway.RBC maintained its sector perform rating on Yum! stock with a $165 price target.Q1 results are due April 29.Price: $162.74, Change: $-0.05, Percent Change: -0.03%

$YUM
Australia

Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule

Cosmos Health (COSM) said Monday that it has completed the first phase execution of its Liv18 liver health supplement ahead of schedule.Production of Liv18 is expected to commence this month, with initial market rollout to follow shortly thereafter, the company said.Cosmos said that based on planned investments in advertising, customer acquisition, and business development, along with early US commercial traction from its other products, Liv18 is expected to generate over $5 million in annual revenue, with gross margins of about 75%.Shares of the company were down more than 6% in Monday's trading.Price: $0.38, Change: $-0.03, Percent Change: -6.47%

$COSM
Australia

Lithium Americas Faces Key Year at Thacker Pass, Wedbush Says

Lithium Americas (LAC) is facing a defining execution year at Thacker Pass, which has evolved from a mining development project into a national security asset, Wedbush Securities said in a Monday note."We see FY26 as a key year for the Thacker Pass buildout with the favorable geopolitical backdrop for domestic lithium production," the report said.The note said construction momentum is building at the project and is fully funded through first production. It said Thacker Pass is underpinned among others by the world's largest known measured lithium resource, a $2.23 billion Department of Energy loan, and a GM joint venture with a 20-year offtake deal.Wedbush kept its neutral rating and $8 price target, saying that execution risk remains the primary overhang.Price: $5.06, Change: $+0.22, Percent Change: +4.44%

$GM$LAC